Mesenchymal Stem Cell Conditioning Promotes Rat Oligodendroglial Cell Maturation

Janusz Joachim Jadasz¹, David Kremer¹, Peter Götte¹, Nevena Tzekova¹, Julia Domke¹, Francisco J. Rivera²³⁴, James Adjaye⁵, Hans-Peter Hartung¹, Ludwig Aigner²⁴, Patrick Küry¹*

¹Department of Neurology, Medical Faculty, University of Düsseldorf, Düsseldorf, Germany, ²Wellcome Trust and MRC Cambridge Stem Cell Institute & Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom, ³Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria, ⁴Institute for Stem Cell Research and Regenerative Medicine, Medical Faculty, University of Düsseldorf, Düsseldorf, Germany

Abstract

Oligodendroglial progenitor/precursor cells (OPCs) represent the main cellular source for the generation of new myelinating oligodendrocytes in the adult central nervous system (CNS). In demyelinating diseases such as multiple sclerosis (MS) myelin repair activities based on recruitment, activation and differentiation of resident OPCs can be observed. However, the overall degree of successful remyelination is limited and the existence of an MS-derived anti-oligodendrogenic milieu prevents OPCs from contributing to myelin repair. It is therefore of considerable interest to understand oligodendroglial homeostasis and maturation processes in order to enable the development of remyelination therapies. Mesenchymal stem cells (MSC) have been shown to exert positive immunomodulatory effects, reduce demyelination, increase neuroprotection and to promote adult neural stem cell differentiation towards the oligodendroglial lineage. We here addressed whether MSC secreted factors can boost the OPC’s oligodendrogenic capacity in a myelin non-permissive environment. To this end, we analyzed cellular morphologies, expression and regulation of key factors involved in oligodendroglial fate and maturation of primary rat cells upon incubation with MSC-conditioned medium. This demonstrated that MSC-derived soluble factors promote and accelerate oligodendroglial differentiation, even under astrocytic endorsing conditions. Accelerated maturation resulted in elevated levels of myelin expression, reduced glial fibrillary acidic protein expression and was accompanied by downregulation of prominent inhibitory differentiation factors such as Id2 and Id4. We thus conclude that apart from their suggested application as potential anti-inflammatory and immunomodulatory MS treatment, these cells might also be exploited to support endogenous myelin repair activities.

Citation: Jadasz JJ, Kremer D, Götte P, Tzekova N, Domke J, et al. (2013) Mesenchymal Stem Cell Conditioning Promotes Rat Oligodendroglial Cell Maturation. PLoS ONE 8(8): e71814. doi:10.1371/journal.pone.0071814

Editor: Fernando de Castro, Hospital Nacional de Parapléjicos - SESCAM, Spain

Received March 22, 2013; Accepted July 2, 2013; Published August 12, 2013

Copyright: © 2013 Jadasz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Christiane and Claudia Hempel Foundation as well as in part by the James and Elisabeth Cloppenburg, Peek & Cloppenburg Düsseldorf Stiftung and the Research Commission of the Medical Faculty of Heinrich-Heine-University. The MS Center at the Department of Neurology is supported in part by the Walter-and-Ilse Rose Stiftung. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: kuery@uni-duesseldorf.de

Introduction

Multiple sclerosis (MS) is the most common chronic inflammatory disease of the central nervous system (CNS) and a leading cause of fixed neurological disability of young adults in Western countries. MS is mediated by an immune response against myelin sheaths and myelin-producing cells, the oligodendrocytes. Degeneration and loss of myelin leave axons unprotected and slow down or even block saltatory conduction of electrical signals which contributes to clinical impairment. Moreover, naked axons are highly susceptible to the overall inflammatory environment ultimately resulting in neuronal damage and neurodegeneration, the extent of which dictates the level of permanent neurological disability. Although repair activities are generally limited within the adult CNS, a certain degree of remyelination can be observed. This regenerative process is dependent on successful cell replacement, which is mainly mediated via endogenous oligodendroglial progenitor/precursor cell (OPC) activation [1]. Unfortunately, overall remyelination efficiency remains poor due to limited cellular differentiation and migration [2,3] or as a consequence of astrocytic cues, such as bone morphogenetic proteins (BMPs), as they have been shown to instruct progenitor cells to differentiate into glial cells expressing astrocyte characteristics [4].

In light of the increasing number of potent immunomodulatory therapies for MS which allow for efficient control of inflammatory relapse activity and preventing further tissue damage [5], the current focus in exploring new MS treatments has shifted towards neuroprotection and functional tissue repair [6]. Regarding the restoration of axonal connectivity and fast signal transmission, recent experimental studies have unravelled a series of distinct molecular switches responsible for the homeostasis and differentiation of stem- and precursor cells within the inflamed tissue [3]. Despite this increasing knowledge on myelinating cell turnover, an integrative translational therapeutic approach aiming at cell-based glial protection and restoration of myelin integrity remains an unmet therapeutic goal. Thus, apart from limiting or re-dressing the deviated immune response, novel methods to support functional regeneration are required.
Mesenchymal stem cells (MSCs) have been shown to exert positive immunomodulatory effects [7], to reduce demyelination [9], to enhance neuroprotection [9] and to promote adult neural stem cell (aNSC) differentiation towards the oligodendroglial lineage at the expense of astrocytes and neurons [10,11]. Secreted factors remain to be elucidated, with the exception of hepatocyte growth factor (HGF), which has been described as a mediator of recovery in MS models [12]. Moreover, ciliary neurotrophic factor (CNTF) was found to foster stem cell derived oligodendrogenesis but appears not to be an MSC-derived key regulator [13].

Here we investigated to what extent OPCs, as the main cellular source for remyelination, are actively determined and supported in their differentiation process towards myelin building mature oligodendrocytes upon stimulation with soluble mesenchymal factors. We found that MSC-conditioned medium supports oligodendroglial fate decision under astrocytic endorsing conditions enhancing the expression of differentiation markers and promoting morphological maturation. Accelerated maturation featured elevated levels of 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase) and myelin basic protein (MBP) expression and reduced glial fibrillary acidic protein (GFAP) expression. This process was accompanied by downregulation of prominent inhibitory differentiation factors such as Id2 and Id4 and could not be mimicked by HGF. We thus conclude that apart from their suggested role as a prospective anti-inflammatory MS treatment these cells might also be applied in order to support endogenous myelin repair activities.

Materials and Methods

Ethics Statement

All cell preparations and all animal care were carried out in accordance with the European Communities Council Directive (86/609/EEC). Furthermore, we received from the ethics committee of the animal research facility of the Heinrich-Heine-University permits to kill animals and to preserve tissues (O69/2011; O118/11). Ethical considerations and details on the generation of primary oligodendroglial cells as well as of mesenchymal stem cells have previously been reported by us [10,14–16].

Mesenchymal Stem Cell Preparation and Medium Conditioning

Bone marrow plugs were harvested from femoral and tibial bone of 2–4 month-old female Fisher rats (Charles River Deutschland GmbH, Germany). Adult rats were anesthetized using ISOFLURAN (DeltaSelect, Langenfeld, Germany) and killed by decapitation. Plugs were mechanically dissociated in Minimum Essential Medium alpha Medium (α-MEM) (Gibco Cell Culture, Life Technologies, Germany) and recovered by centrifugation. Cell pellets were resuspended in α-MEM containing 10% fetal bovine serum (α-MEM-10%FBS; PAN Biotech GmbH, Germany) and seeded at 1x10^6 cells/cm² in a humidified incubator at 37°C with 5% CO2. After three days, the entire culture was used and designated as bone marrow cells (BMCs) or separated into non-adherent cells and adherent cells. Adherent cells were incubated in fresh α-MEM-10%FBS as standard/control medium (designated as α-MEM from here on) until a confluent layer of cells was reached. These cells were trypsinized using a 0.25% Trypsin-EDTA solution (Gibco Cell Culture, Life Technologies, Germany), seeded in α-MEM-10%FBS at 8,000 cells/cm². After 3–5 days of culture, the resulting monolayer of cells, hereafter named rat bone marrow-derived mesenchymal stem cells (MSCs), was trypsinized and frozen or further cultured.

Figure 1. MSC-CM stimulates morphological maturation of OPCs. Mesenchymal stem cell conditioned medium (MSC-CM) accelerates maturation of cultured oligodendroglial progenitors cells. We identified six distinct morphologies (see bottom), from a very low number of processes in progenitor cells to multiple process-bearing cells (low, medium, high) to mature cells with a very high degree of arborisation or flattened appearance (sheaths). (A–D) Analysis of OPC morphology distribution revealed an MSC-CM-dependent shift towards more mature cells (black bars α-MEM treated cells; grey bars MSC-CM stimulated cells) after one (A), three (B), six (C) and nine days (D). (E,F) Representative citrine labelled OPCs revealing advanced morphologies and promoted sheath formation (arrows) upon MSC-CM stimulation after nine days. Data are shown as mean values ± SEM derived from n = 5 experiments. t-test (ns: not significant, * P<0.05; ** P<0.01; *** P<0.001). Scale bar: 50 μm.

doi:10.1371/journal.pone.0071814.g001
Figure 2. MSC-CM leads to enhanced early myelin expression. Determination of transcript levels by means of quantitative real-time RT-PCR. (A) Upregulation of ceramide galactosyltransferase (CGT) expression was detected after three, six and nine days in culture, (B) whereas gene expression levels of CNPase were elevated at every measured time point. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression was used as reference. (C) In addition, an increased percentage of CNPase-expressing OPCs was observed among MSC-CM treated cells as compared to cells.
grown in α-MEM. Significant differences were detected from day three onwards. (D–E’’) Representative immunofluorescent stainings of CNPase expressing OPCs at all four time points of investigation. Data are shown as mean values ± SEM and derive from n = 8 (CNPase, q-RT-PCR) and n = 4 (CNPase, immunostainings) experiments. t-test (* P<0.05; ** P<0.01; *** P<0.001). Scale bars: 50 μm.

doi:10.1371/journal.pone.0071814.g002

Figure 3. MSC-CM enhances myelin basic protein expression. (A) Gene expression levels of MBP are up-regulated after one, three, six and nine days in MSC-CM. (B) Determination of the degree of MBP-positive OPCs as revealed by immunostainings show a significantly increased number after MSC-CM treatment for six and nine days. (C) Western blot analysis shows increased MBP protein levels after six days in mesenchymal stem cell conditioned medium. GAPDH was used as internal reference. (D–E’’) Representative immunofluorescent stainings of MBP expressing OPCs at all four time points of investigation. Data are shown as mean values ± SEM derived from n = 6 (q-RT-PCR) and n = 3 (immunostainings, Western Blot) experiments. t-test (* P<0.05; ** P<0.01, *** P<0.001). Scale bars: 50 μm.

doi:10.1371/journal.pone.0071814.g003
MSC-conditioned medium (MSC-CM) was prepared by plating 12,000 MSCs per cm² and incubation in α-MEM-10% FBS or α-MEM-1% FBS for three days. Conditioned media were not diluted and directly applied to OPCs 4 h to 6 h after plating. HGF (R&D Systems, Minneapolis, MN) was applied at a final concentration of 50 ng/ml in α-MEM-10% FBS according to Bai and colleagues [12]. For HGF neutralization experiments, α-MEM-10% FBS and MSC-CM were incubated at 37°C with a final concentration of 10 μg/ml function-blocking anti-HGF antibody (R&D Systems) for 1 h before use as previously published [12].

Oligodendroglial Cell Culture

Purification and culturing of OPCs was performed according to earlier descriptions [17]. Briefly, P1 rats were anesthetized using ISOFLURAN and killed by decapitation. Dissociated P1 rat cortices were cultured on poly-D-lysine (PDL)-coated cell culture flasks in DMEM substituted with 10% FBS and 4 mM L-glutamine. After 10 days, flasks were shaken at 250 rev/min for 2 h to deplete from microglial contamination. Then flasks were shaken for another 20 h in which OPCs were dislodged from the underlying astrocyte-layer and replated on PDL-coated culture dishes or glass cover slips in high glucose DMEM-Sato-based medium containing bovine 5 μg/mL insulin, 50 μg/mL human insulin, 100 μg/mL albumin, 5 μg/mL transferrin, 50 ng/mL selenium, 5 μg/mL sodium pyruvate, 20 μM nonessential amino acids, 10 mM HEPES, 100 μM β-mercaptoethanol, and 25 mM glucose.

Figure 4. MSC-CM treatment enhances OPC proliferation, while cell death rate remains low. (A) Anti-Ki67 immunofluorescent stainings and evaluation of positive cells revealed a higher proliferation rate under MSC-CM treatment as compared to α-MEM, whereas (B) cell death rates remained low under both conditions with a minor significant survival effect upon MSC-CM treatment at six days. Data are shown as mean values ± SEM derived from n = 4 experiments. t-test (ns: not significant, * P<0.05, **P<0.01).

doi:10.1371/journal.pone.0071814.g004

Figure 5. MSC-CM dependent regulation of early OPC markers. (A) Determination of the degree of A2B5 positive cells as revealed by immunofluorescence stainings. α-MEM and MSC-CM were given to the cells after four hours. (B) Determination of the degree of weak and strong Olig2 expressing cells during the course of α-MEM and MSC-CM stimulation up to nine days. (C–H’) Representative immunofluorescent stainings of Olig2 expressing OPCs at all three time points. Arrowheads mark weak expressing cells, whereas arrows point to strong expressors. Data are shown as mean values ± SEM derived from n = 3 (A2B5) and n = 4 (Olig2) experiments. t-test (ns: not significant, * P<0.05; **P<0.01; *** P<0.001). Scale bar: 50 μm.

doi:10.1371/journal.pone.0071814.g005
transferrin, 100 μg/mL BSA, 6.2 μg/mL progesterone, 16 μg/mL putrescine, 5 ng/mL sodium selenite, and 4 mM L-glutamine (all Sigma-Aldrich, Missouri, USA). After cell sedimentation (4 to 6 h after plating) the medium was changed after one washing step with PBS to control medium or MSC-CM (no further dilution), which was changed every third day. For morphological staging, OPCs were transfected with a citrine expression vector and morphologies were determined by means of a morphological key as previously described in [14,15].

RNA Preparation, cDNA Synthesis and Quantitative Reverse Transcription (RT)-PCR

Prepared OPCs were cultured for up to nine days in α-MEM or MSC-CM. Total RNA purification from cells was done using the RNeasy procedure (Qiagen, Hilden, Germany). Isolated RNA was reverse transcribed using the high capacity cDNA Reverse Transcript Kit (Applied Biosystems, Darmstadt, Germany). Quantitative determination of gene expression levels was performed on a 7900HT sequence detection system (Life Technologies, Applied Biosystems, Darmstadt, Germany) using Power SybrGreen universal master mix (Applied Biosystems). Primer sequences were determined using PrimerExpress 2.0 software (Applied Biosystems) and tested for the generation of specific amplicons: GFAP_fwd: CTG GTG TGG AGT GCC TTC GT, GFAP_rev: CAC CAA CGA GCT TCC GAG AG, CGT_fwd: CCG GCC ACC CTT TCA AT, CGT_rev: GAG GGA GAG TCA CCA AGT, CNPase_fwd: CTG CCG CCG GGA CAT, CNPase_rev: TGC CCG TCC TGG TGT GGA T, MBP_fwd: CCA TGG ACC CCA CAG GAA AC, MBP_rev: TGG CAT CTC CAG CGT GTT C, Id2_fwd: AGA ACC AAA CGG TCA GGA CG, Id2_rev: TGG TGA TGT TCA CGG TCG TTA GG, Id4_fwd: CAG CTG CAG GTC CAG GAT GT,

Figure 6. Downregulation of GFAP expression following stimulation with MSC-CM. OPCs were plated for four hours in SATO medium before changing the medium to control (α-MEM) or to mesenchymal stem cell conditioned medium (MSC-CM) and analysis after one, three, six and nine days. (A) Consistently decreased GFAP transcript levels were detected at every time point using quantitative real-time RT-PCR. (B) Determination of the degree of GFAP-positive OPCs revealed increasing numbers among α-MEM treated cells whereas MSC-CM stimulation stabilized low GFAP expression levels. (C–D’’) Representative anti-GFAP immunofluorescent stainings. Data are shown as mean values ± SEM derived from n = 3 for both, q-RT-PCR as well as immunostaining experiments. t-test (*** P < 0.001). Scale bars: 50 μm.

doi:10.1371/journal.pone.0071814.g006
Id4_rev: AAA GTG GAG ATC CTG CAG CAC, GAPDH_fwd: GAA CGG GAA GCT CAC TGG C, GAPDH_rev: GCA TGT CAG ATC AAC TG C, ODC_fwd: GGT TCC AGA GGC CAA ACA TC, ODC_rev: GTT GCC ACA TTG ACC GTG AC. GAPDH and ODC were used as reference genes; data are shown as mean values ± SEM and t-test was applied in order to determine statistical significance (Prism 5.0c; GraphPad Software).

Immunohistochemical Procedures

For marker expression analysis, OPCs were fixed with 4% paraformaldehyde/PBS solution, PBS washed, blocked for 45 minutes using 1% normal goat serum and 1% Triton in PBS and subjected to antibody incubation at 4°C overnight: mouse anti-myelin basic protein (MBP) (1:500, Sternberger Monoclonals, Lutherville, MD), mouse anti-2',9',3'9'-cyclic nucleotide 3'9'-phosphodiesterase (CNPase) (1:500, Sternberger Monoclonals), rabbit anti-cleaved Caspase3 (1:500, Cell Signaling Technology, Leiden, The Netherlands), rabbit anti-Ki67 (1:500, Millipore, Schwabach, Germany), rabbit anti-GFAP (1:1000, Dako, Hamburg, Germany), mouse anti-GFAP (1:1000, Millipore), mouse anti-A2B5 (1:200, Millipore) and rabbit anti-Olig2 (1:1000, Millipore). Following PBS washes secondary anti-mouse and anti-rabbit antibodies conjugated with either Alexa Fluor594 or Alexa Fluor488 (1:1000, Invitrogen) were added for 2 h at room temperature. Nuclei were stained with 4',6-diamidino-2-phenylindole (Roche). Cells were mounted under Citifluor (Citifluor, Leicester, UK) and analyzed using an Axio Cam HRc microscope (Zeiss, Jena, Germany). HGF-ELISA was performed using Mouse/Rat HGF Quantikine ELISA kit according to the protocol of the supplier (R&D Systems). Absolute cell numbers were determined using the nucleus counter macro of the ImageJ 1.46e software.

Western Blot Analysis

Lysis of control and MSC-CM treated OPCs was carried out on ice with radioimmuno-precipitation assay buffer (RIPA buffer; Cell Signaling Technology, Danvers, Massachusetts, USA) with addition of Halt protease inhibitor cocktail (Thermo Scientific, Rockford, IL, USA). Specimens were subjected to two sonification cycles of 15 s each, and protein solutions were kept on ice for 1 min between the pulses. Protein concentrations were determined using the DC Protein Assay (BioRad, München, Germany). Probes were subjected to standard SDS gel electrophoresis and

Figure 7. Serum reduced conditioned medium. Determination of transcript levels by means of quantitative real-time RT-PCR. Investigation of GFAP, Id2 and Id4 gene expression levels in α-MEM versus MSC-CM containing 10% FBS (A,C,E). Investigation of GFAP, Id2 and Id4 gene expression levels in α-MEM versus MSC-CM containing 1% FBS (B,D,F). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression was used as reference gene; data are shown as mean values ± SEM derived from n = 7 for Id2, Id4 and n = 3 for GFAP (A,C,E) and n = 3 (B,D,F) experiments. t-test (ns: not significant, * P<0.05, **P<0.01, *** P<0.001). doi:10.1371/journal.pone.0071814.g007
Figure 8. HGF does not mimic MSC-CM mediated cellular effects. (A) Determination of HGF protein content in stimulation media by means of ELISA revealing a robust increase upon MSC conditioning. (B) No difference regarding CNPase positivity was observed among OPCs grown in α-MEM in the absence or presence of recombinant HGF, whereas MSC-CM reproducibly increased CNPase expression. (C–E) Determination of transcript levels by means of quantitative real-time RT-PCR. No significant differences regarding Id2, Id4 and GFAP transcript levels were observed among OPCs grown in α-MEM in the absence or presence of recombinant HGF. MSC-CM treatment significantly reduced transcript levels of all three genes at all time points. (F–K) Anti-HGF antibody mediated depletion experiments revealed no effect on astrocyte (GFAP, Id2, Id4) and oligodendroglial/myelin
Western blotting using RunBlue SDS gels (Expeodon, Cambridge-shire, UK), RunBlue Blot Sandwich nitrocellulose (Expeodon) applying mouse anti-MBP (MBP; Covance; 1:500, Princeton, New Jersey, USA), mouse anti-galactosylceramide (GalC). CGT was significantly increased by 3-fold after six and nine days compared to control (Fig. 2A). Of note, at late time points a markedly increased degree of sheath forming cells was detected (Fig. 1D,E,F) indicating that secreted mesenchymal stem cell factors exert a positive effect on oligodendroglial maturation kinetics as well as on process fusion and sheath generation.

MSC-CM Leads to Increased Levels of Myelin Expression

A main component of oligodendroglial cell maturation is the expression of myelin markers. We therefore evaluated transcript levels of the ceramide galactosyltransferase (CGT) gene, which encodes an enzyme known to synthesize the myelin component galactosylceramide (GaIC). CGT was significantly increased by 3-fold in OPCs after MSC-CM treatment for three days and by 2.5-fold after six and nine days compared to control (Fig. 2A). Additionally, transcript levels of the early myelin marker CNPase were induced from one to nine days of treatment (Fig. 2B). To evaluate, whether CNPase protein levels were also elevated, we stained and determined the percentage of CNPase positive cells in both conditions. This demonstrated that in OPC populations treated with MSC-CM, CNPase protein expression is strongly and significantly increased at time points three, six and nine days after stimulation (Fig. 2G–E’’’). Likewise the degree of MBP-expressing OPCs was elevated with significant changes on gene expression levels at every time-point (Fig. 3A), and after six and nine days of treatment for protein levels (Fig. 3B,D–E’’’ as well as in Western blot analysis (Fig. 3C)). To confirm that these observed effects were not based on selection processes, we examined proliferation and cell death of control medium and MSC-CM treated OPCs. During the culture of OPCs, proliferation rates gradually decreased but were slightly increased in the presence of mesenchymal secreted factors with significant alterations found after three, six and nine days (Fig. 4A). The percentage of Caspase3-positive OPCs between the two conditions was only altered significantly on day six, though the overall Caspase3-positivity remained low (Fig. 4B).

In order to determine, whether mesenchymal stem cell-derived factors affect oligodendroglial fate decision and stability, we investigated expression of early markers such as A2B5 and Olig2. These experiments confirmed that the majority of plated cells are A2B5 positive and that the expression is decreased under α-MEM conditions whereas it is increased upon MSC-CM treatment (Fig. 5A). Likewise, MSC-CM treatment increased the percentage of both weak as well as of strong Olig2 expressors as opposed to strongly decreased levels under α-MEM conditions (Fig. 5B–H’).

Regulation of Astroglial Factors

We next analyzed, whether the astrocyte marker glial fibrillary acidic protein (GFAP) was regulated by MSC-CM. Indeed, OPCs incubated with MSC-CM displayed strongly reduced GFAP transcript levels and a significantly lowered degree of GFAP positivity (Fig. 6). This was in contrast to cells grown in α-MEM featuring a gradual increase in GFAP protein expression over time, thereby accumulating astrocytic features and gaining astrocytic morphologies. In accordance to Ki67 and Caspase-3 data presented above (Fig. 4), we conclude that the increase of GFAP positive cells in α-MEM cannot derive from either increased proliferation or promoted survival of astrocytic cells. Moreover, given the known astrogliogenic potential of high serum containing media, we generated MSC-CM based on α-MEM containing 1% FBS only (instead of 10% FBS as shown in Fig. 6). We directly compared gene expression levels in high an low serum containing media and observed that although the astrogliogenic pressure is lower under serum-reduced conditions, MSC-CM can still efficiently counteract the induction of astrocytic features. However, the extent and temporal profiles of GFAP expression revealed to be slightly different (Fig. 7A compare to Fig. 7B).

Initially described as O-2A cells [18], OPCs exert a certain degree of multipotency which under particular circumstances can also give rise to astrocytes [19]. Promotion of astrogliosis has also been reported for the α-MEM medium which was applied in this study in particular due to the presence of fetal bovine serum (FBS) [10,20,21]. Furthermore, transcriptional regulators such as inhibitor of differentiation 2 (Id2) and inhibitor of differentiation 4 (Id4) have been described to control glial differentiation acting also as inhibitors of myelin expression [22,23]. We therefore examined whether MSC-CM plays a role in fate decision of immature OPCs via regulation of Id2/Id4 expression levels and detected significantly decreased Id2 and Id4 transcript levels in OPCs upon MSC-CM stimulation at all time points (Fig. 7C,E). Of note, similar Id regulations were observed when low serum MSC-CM was applied (Fig. 7D,F). However, due to the lowered astrogliogenic potential of serum reduced medium, gene expression levels were lower as compared to the 10% FBS containing media.
Hepatocyte Growth Factor as a Secreted MSC-CM Factor is not the Critical Component for OPC Differentiation

The composition of mesenchymal stem cell secreted factors and their molecular interactions are still poorly understood. Among the few identified molecules is hepatocyte growth factor (HGF), which has been shown to mediate mesenchymal stem cell-induced recovery in animal MS models [12]. We therefore evaluated whether HGF is also a key regulator of the described MSC-CM effect exerted on immature OPCs. To this end, we determined HGF content using enzyme linked immunosorbent assay (ELISA) revealing a significant enrichment of HGF in MSC-CM after a three days incubation of MSCs with α-MEM containing either 10% or 1% FBS (Fig. 8A). To clarify, whether HGF exerts an oligodendroglial differentiation effect, we quantified CNPase-positive cells in α-MEM supplemented with 50 ng/ml recombinant HGF. Importantly, we did not observe any significant differences between α-MEM cultured with or without HGF whereas both conditions induced significantly lower CNPase expression levels compared to MSC-CM (Fig. 8B). Moreover, GFAP expression levels of cells grown in α-MEM plus HGF were similar to those kept in α-MEM (Fig. 8C). Likewise, Id2/4 transcript levels were also not down-regulated by HGF, as compared to α-MEM grown cells, and were even further increased after three and six days in culture (Fig. 8D,E). We also analyzed gene expression levels after neutralizing HGF with a function-blocking antibody based on previously published conditions [12]. We analyzed GFAP, Id2, Id4, CGT, MBP and CNPase gene expression levels at time-point nine days of stimulation. Importantly, we did not detect any differences between media without and media with anti-HGF antibodies (Fig. 8F-K), further supporting that HGF is not involved in the MSC-CM dependent fate and differentiation effect.

Discussion

Oligodendroglial cell maturation is coordinated by different factors either stimulating or inhibiting differentiation processes. Here, we demonstrate that mesenchymal stem cell secreted factors of yet unknown identity support and enforce cell fate decisions and promote differentiation and maturation towards oligodendrocytes. Furthermore, a slight MSC-CM mediated increase in OPC proliferation was observed which is in line with previous data on the control of neural stem cell proliferation [24].

The observation that OPCs did not develop astrocytic features and morphologies in the presence of mesenchymal stem cell-secreted components leads to the assumption that cell fate decisions are regulated. Although currently unidentifed, this mixture of factors apparently influences glial transcription patterns – some of the regulated genes being dependent on Olig2 and Id-mutated bHLH transcriptional activities. In this regard, the regulation of Id2 and Id4 is most noteworthy as, for the first time, it demonstrates a glial cell regulatory effect based on mesenchymal stem cells independent of FBS concentration in the medium used for conditioning. Since adding as well as neutralizing HGF turned out to be ineffective in either reversing the fate of fetal bovine serum containing medium instructed cells or in supporting oligodendroglial differentiation, future investigations will have to address the nature of the underlying conditioning factors. It is likely that it will be a cocktail of different ingredients that proves to be essential with perhaps different combinations acting on fate decisions while others influence particular maturation steps. Moreover, the finding that HGF is not the responsible trophic substance is in agreement with previous findings on an HGF-dependent blockade under oligodendroglial differentiation permissive conditions [25]. Of note, we have previously described that another MSC-derived factor, ciliary neurotrophic factor (CNTF), is also not part of the soluble activity acting on aNSCs [13].

The finding of an MSC-CM-dependent counteracting of astrocytic cues leads to the hypothesis that mesenchymal stem cells have the potential to also activate resident stem- and precursor cells upon therapeutic transplantation (locally or systemically). In light of the fact that in contrast to niche-derived NSCs, resident OPCs represent a widespread and dispersed cell population in the CNS promotion of endogenous repair activities by activated and fate-stabilized OPCs provides important advantages. Together with the proliferative enhancement of early progenitor cells and in addition to their proven immunomodulatory effects, these features could indeed contribute to successful myelin repair in vivo. Of note, bone morphogenetic protein (BMP) signalling leading to increased Id4 and decreased Olig2 expression has been shown to cause astrocyte differentiation of OPCs [26]. Additionally, after demyelinating injuries, BMPs were shown to promote gliosis [27] and subsequent glial scar formation which interferes with axonal restoration as well as remyelination. Our findings therefore also suggest that MSC-CM pre-treated exogenous OPCs could be a valuable tool for functional exogenous cell replacement helping to withstand astrocytic lesion cues.

Lindsay and colleagues recently demonstrated that conditioning effects may differ between MSCs derived from different tissues, with human mesenchymal stem cells from the lamina propria having the ability to enhance in vivo myelination whereas bone marrow-derived cells failed to do so [28]. However, their study focused on oligodendroglial cells which had been cultured for seven days in medium supplemented with growth factors and which are therefore most likely more advanced in terms of fate stabilisation and maturation as well as on olfactory ensheathing cells (OECs). Nevertheless, this study suggests that mesenchymal cocktails are origin-specific, a notion that might be experimentally explored in the future for the identification of active components.

In conclusion, our study provides strong evidence for cell fate decision- as well as differentiation promoting properties of secreted mesenchymal stem cell factors acting on OPCs. As these resident progenitor cells constitute the major source for myelinating glial cell replacement in demyelinating CNS diseases, stimulation of endogenous repair activity by means of MSC transplantation or administration of responsible underlying trophic factors represents an attractive therapeutic approach.

Supporting Information

Table S1 Absolute numbers of counted cells in this study. For each counting at least three different experiments per condition were analyzed. (XLSX)

Acknowledgments

We thank Brigida Ziegler, Felix Beyer and Moritz Förster for technical support and the anonymous reviewers for their comments improving the quality of this study.

Author Contributions

Conceived and designed the experiments: JJJ DK PG NT FJR HPH LA PK. Performed the experiments: JJJ DK PG NT JD FJR. Analyzed the data: JJJ DK PG NT JD FJR HPH LA PK. Contributed reagents/materials/analysis tools: JJJ FJR JA LA PK. Wrote the paper: JJJ JA HPH LA PK.
References

1. Chang A, Nishiyama A, Peterson J, Primeas J, Trapp BD (2000) NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci 20: 6404–6412.

2. Kremer D, Aktas O, Hartung HP, Kory P (2011) The complex world of oligodendroglial differentiation inhibitors. Ann Neurol 69: 602–618.

3. Kotter MR, Stadelmann C, Hartung HP (2011) Enhancing remyelination in disease–can we wrap it up? Brain 134: 1902–1900.

4. Mahie PC, Mehler MF, Marmur R, Papavasiliou A, Song Q, et al. (1997) Bone morphogenetic proteins induce astroglial differentiation of oligodendroglial-astroglial progenitor cells. J Neurosci 17: 4112–4120.

5. Aktas O, Kieseier B, Hartung HP (2010) Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci 33: 149–152.

6. Mullard A (2011) Success of immunomodulators in MS shifts discovery focus to neuroprotection. Nat Rev Drug Discov 10: 885–887.

7. Aggarwal S, Fittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105: 1815–1822.

8. Gordon D, Pavlovska G, Uney JB, Wraith DC, Scolding NJ (2010) Human mesenchymal stem cells infiltrate the spinal cord, reduce demyelination, and localize to white matter lesions in experimental autoimmune encephalomyelitis. J Neuropathol Exp Neurol 69: 1087–1095.

9. Uccelli A, Benvenuto F, Laroni A, Giunti D (2011) Neuroprotective features of mesenchymal stem cells. Best Pract Res Clin Haematol 24: 59–64.

10. Rivera FJ, Couillard-Despres S, Pedre X, Ploetz S, Caioni M, et al. (2006) Mesenchymal stem cells instruct oligodendrogenic fate decision on adult neural progenitors. Stem Cells 24: 2209–2219.

11. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, et al. (2009) Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 57: 1192–1203.

12. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, et al. (2009) Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 57: 1192–1203.

13. Rivera FJ, Kandasamy M, Couillard-Despres S, Caioni M, Sanchez R, et al. (2008) Oligodendrogenesis of adult neural progenitors: differential effects of ciliary neurotrophic factor and mesenchymal stem cell derived factors. J Neurosci 28: 892–904.

14. Kremer D, Heinen A, Jakas JJ, Gotte P, Zimmermann K, et al. (2009) p57kip2 is dynamically regulated in experimental autoimmune encephalomyelitis and interferes with oligodendroglial maturation. Proc Natl Acad Sci U S A 106: 9087–9092.

15. Gotte P, Kremer D, Jander S, Odenis V, Engele J, et al. (2010) Activation of CXCR7 receptor promotes oligodendroglial cell maturation. Ann Neurol 68: 915–924.

16. Steffenhagen C, Dechant FX, Oberbauer E, Farbner T, Weidner N, et al. (2012) Mesenchymal stem cells prime proliferating adult neural progenitors toward an oligodendrocyte fate. Stem Cells Dev 21: 1838–1851.

17. McCarthy KD, de Vellis J (1980) Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85: 890–902.

18. Raff MC, Miller RH, Noble M (1983) A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature 303: 390–396.

19. See J, Mamontov P, Ahn K, Wine-Lee L, Crenshaw EB, et al. (2007) BMP signaling mutant mice exhibit glial cell maturation defects. Mol Cell Neurosci 35: 171–182.

20. Jadaz JJ, Rivera FJ, Taubert A, Kandasamy M, Sandner B, et al. (2012) p57kip2 regulates glial fate decision in adult neural stem cells. Development 139: 3306–3315.

21. Gard AL, Williams WC, 2nd, Barrell MR (1995) Oligodendroblasts distinguished from O-2A glial progenitors by surface phenotype (O4+GalC-) and response to cytokines using signal transducer LIFR beta. Dev Biol 167: 596–608.

22. Kondo T, Raff M (2000) The Id4 HLH protein and the timing of oligodendrocyte differentiation. EMBO J 19: 1980–2007.

23. Wang S, Sdrulla A, Johnson JE, Yokota Y, Barres BA (2001) A role for the helix-loop-helix protein Id2 in the control of oligodendrocyte development. Neuron 29: 603–614.

24. Yao SW, Kim SS, Lee SY, Lee HS, Kim HS, et al. (2008) Mesenchymal stem cells promote proliferation of endogenous neural stem cells and survival of newborn cells in a rat stroke model. Exp Mol Med 40: 387–397.

25. Ohya W, Funakoshi H, Kuroawa T, Nakamura T (2007) Hepatocyte growth factor (HGF) promotes oligodendrocyte progenitor cell proliferation and inhibits its differentiation during postnatal development in the rat. Brain Res 1147: 51–65.

26. Cheng X, Wang Y, He Q, Qiu M, Whitmore SR, et al. (2007) Bone morphogenetic protein signaling and olig1/2 interact to regulate the differentiation and maturation of adult oligodendrocyte precursor cells. Stem Cells 25: 3204–3214.

27. Setoguchi T, Yone K, Matsuoka E, Takenouchi H, Nakashima K, et al. (2007) BMP signaling mutant mice exhibit glial cell maturation defects. Mol Cell Neurosci 35: 390–396.

28. Lindsay SL, Johnstone SA, Mountford JC, Sheikh S, Allan DB, et al. (2013) Human mesenchymal stem cells isolated from olfactory biopsies but not bone enhance CNS myelination in vitro. Glia 61: 368–382.